Expert Opinion on Drug Safety

Papers
(The H4-Index of Expert Opinion on Drug Safety is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Tackling antimicrobial resistance across sub-Saharan Africa: current challenges and implications for the future53
Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety50
Long-term safety of ketamine and esketamine in treatment of depression47
Gastrointestinal and cardiovascular adverse events associated with NSAIDs44
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients42
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients38
A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system38
Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects35
Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines34
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database31
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia30
Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion28
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis27
The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)26
Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis26
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma26
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge24
The therapeutic potential of psilocybin: a systematic review24
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation24
Current and emerging long-acting antipsychotics for the treatment of schizophrenia23
Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review23
Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data21
Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions21
0.044088125228882